Conference Coverage

Consider cyclosporine a go-to for refractory atopic dermatitis in kids


 

REPORTING FROM SPD 2019

– For children and adolescents with severe, refractory atopic dermatitis, Peter A. Lio, MD, often turns to cyclosporine as his systemic treatment of choice.

Dr. Peter A. Lio Assistant professor of clinical dermatology and pediatrics at the Northwestern University Feinberg School of Medicine, Chicago. Doug Brunk/MDedge News

Dr. Peter A. Lio

Cyclosporine “works quickly, and it’s very reliable,” Dr. Lio said at the annual meeting of the Society for Pediatric Dermatology. “In my experience, more than 90% of patients will see significant improvement, but there are real risks, including hypertension, kidney damage, monthly blood work, tremor, hypertrichosis, gum hypertrophy, and cancer/infection risk.”

To mitigate those risks, Dr. Lio, of the departments of dermatology and pediatrics at Northwestern University, Chicago, prescribes cyclosporine for 3-6 months at a dose of 5 mg/kg per day with a cap of 300 mg per day to “to cool things down.” He then transitions patients to phototherapy or mycophenolate right away. “Those are my two favorites,” he said. “Methotrexate can also be used, but I rarely use azathioprine.

“If you do this, you avoid most of the major risks and you can put people in a remission. More than half of the time, maybe two-thirds of the time, I get them into at least a relative remission,” Dr. Lio said.

While patients are on cyclosporine, blood pressure should be monitored each week for 4 weeks, and then monthly, he said. Draws for complete blood count, liver function tests, comprehensive metabolic panel, uric acid, and lipids should be performed monthly for 3 months, then every 8 weeks, he advised. Dr. Lio typically maintains the cyclosporine for 3 months, then tapers patients off the drug.

Patients who continue to struggle for relief might try taking cyclosporine on weekends only, a concept reported by Spanish investigators in 2015 (Pediatr Dermatol 2015 32[4]:551-2). “This involves twice-daily full dosing just on Saturdays and Sundays,” Dr. Lio said. “I now have quite a few patients doing well with this approach.”

Dr. Lio disclosed having financial ties to numerous pharmaceutical companies but none related to cyclosporine.

Recommended Reading

Severity, itch improvements remain steady with ruxolitinib for atopic dermatitis
MDedge Dermatology
Cyclosporine, methotrexate have lowest 6-month infection risk for AD patients
MDedge Dermatology
Real-world experience with dupilumab in AD mirrors clinical trial efficacy
MDedge Dermatology
Round 1: Biologics, JAK inhibitors training up for atopic dermatitis ‘boxing match’
MDedge Dermatology
Neonatal ICU stay found ‘protective’ against risk for developing atopic dermatitis
MDedge Dermatology
Patients with AD should routinely be asked about conjunctivitis
MDedge Dermatology
Topical calcineurin inhibitors are an effective treatment option for pediatric periorificial dermatitis
MDedge Dermatology
A 3-year-old is brought to the clinic for evaluation of a localized, scaling inflamed lesion on the left leg
MDedge Dermatology
Rescue fantasies
MDedge Dermatology
Dupilumab found effective for adolescents with moderate to severe AD
MDedge Dermatology